Loading... Please wait... Loading... Please wait...
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
The AlterG NEO combines updated user-friendly design with trusted Anti-Gravity technology for precise and consistent unweighting in physical rehabilitation and athletic training...
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader d...
ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) – Analysts at HC Wainwright lifted their Q2 2024 earnings per share (EPS) estimates for ReWalk Robotics in a research report issued on Thur...
ReWalk Robotics (LFWD) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.49 per share a year ago....
Q1'24 revenue of $5.3M is up 340% vs. Q1'23 and at the midpoint of Lifeward's guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1'24 results Medicare...
ReWalk (LFWD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....
Invest in companies like Option Care Health (OPCH), ReWalk Robotics Ltd. (LFWD) and Garmin (GRMN), as they boast higher efficiency levels....
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader de...
ReWalk (LFWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
